About: Impact of Outpatient Neuraminidase Inhibitor Treatment in Patients Infected With Influenza A(H1N1)pdm09 at High Risk of Hospitalization: An Individual Participant Data Metaanalysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Impact of Outpatient Neuraminidase Inhibitor Treatment in Patients Infected With Influenza A(H1N1)pdm09 at High Risk of Hospitalization: An Individual Participant Data Metaanalysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Impact of Outpatient Neuraminidase Inhibitor Treatment in Patients Infected With Influenza A(H1N1)pdm09 at High Risk of Hospitalization: An Individual Participant Data Metaanalysis
Creator	Nguyen-Van-Tam, Jonathan Schweiger, Brunhilde Al Masri, Malak Gérardin, Patrick Tran, Dat Memish, Ziad Rath, Barbara Myles, Puja Loh, Tze Miller, Elizabeth Tang, Julian Koay, Evelyn Andrews, Nick Venkatesan, Sudhir Bantar, Carlos Dubnov-Raz, Gal Muthuri, Stella Oliva, Maria Vidmar, Tjasa Leonardi-Bee, Jo Waight, Pauline
source	PMC
abstract	BACKGROUND. While evidence exists to support the effectiveness of neuraminidase inhibitors (NAIs) in reducing mortality when given to hospitalized patients with A(H1N1)pdm09 virus infection, the impact of outpatient treatment on hospitalization has not been clearly established. We investigated the impact of outpatient NAI treatment on subsequent hospitalization in patients with A(H1N1)pdm09 virus infection. METHODS. We assembled general community and outpatient data from 9 clinical centers in different countries collected between January 2009 and December 2010. We standardized data from each study center to create a pooled dataset and then used mixed-effects logistic regression modeling to determine the effect of NAI treatment on hospitalization. We adjusted for NAI treatment propensity and preadmission antibiotic use, including “study center” as a random intercept to account for differences in baseline hospitalization rate between centers. RESULTS. We included 3376 patients with influenza A(H1N1)pdm09, of whom 3085 (91.4%) had laboratory-confirmed infection. Eight hundred seventy-three patients (25.8%) received outpatient or community-based NAI treatment, 928 of 2395 (38.8%) with available data had dyspnea or respiratory distress, and hospitalizations occurred in 1705 (50.5%). After adjustment for preadmission antibiotics and NAI treatment propensity, preadmission NAI treatment was associated with decreased odds of hospital admission compared to no NAI treatment (adjusted odds ratio, 0.24; 95% confidence interval, 0.20–0.30). CONCLUSIONS. In a population with confirmed or suspected A(H1N1)pdm09 and at high risk of hospitalization, outpatient or community-based NAI treatment significantly reduced the likelihood of requiring hospital admission. These data suggest that community patients with severe influenza should receive NAI treatment.
has issue date	2017-05-15(xsd:dateTime)
bibo:doi	10.1093/cid/cix127
bibo:pmid	28199524
has license	cc-by
sha1sum (hex)	ea09ec37bc9bebaeffe4fb4f1c505677b3c9f644
schema:url	https://doi.org/10.1093/cid/cix127
resource representing a document's title	Impact of Outpatient Neuraminidase Inhibitor Treatment in Patients Infected With Influenza A(H1N1)pdm09 at High Risk of Hospitalization: An Individual Participant Data Metaanalysis
has PubMed Central identifier	PMC5411393
has PubMed identifier	28199524
schema:publication	Clin Infect Dis
resource representing a document's body	covid:ea09ec37bc9bebaeffe4fb4f1c505677b3c9f644#body_text
is schema:about of	named entity 'exists' named entity 'While' named entity 'Clinical Infectious Diseases' named entity 'Impact' named entity 'Influenza A(H1N1)' named entity 'Neuraminidase' named entity 'MORTALITY' named entity 'NAI' named entity 'HOSPITALIZATION' named entity 'HIGH RISK OF' named entity 'A(H1N1)' named entity 'virus' named entity 'neuraminidase' named entity 'infection' named entity 'neuraminidase inhibitors' named entity 'Influenza' named entity 'comorbid' named entity 'Tamiflu' named entity 'Clinical Infectious Diseases' named entity 'H1N1' named entity 'IPD' named entity 'influenza' named entity 'PROSPERO' named entity 'H1N1' named entity 'pneumonia' named entity 'heterogeneity' named entity 'pediatric' named entity 'ambulatory care' named entity 'outpatient' named entity 'vaccination' named entity 'high-risk' named entity 'influenza' named entity 'respiratory distress' named entity 'F. Hoffmann-La Roche' named entity 'symptom' named entity 'influenza' named entity 'high-risk' named entity 'United Kingdom' named entity 'symptom' named entity 'stratified analysis' named entity 'confounding' named entity 'interquartile range' named entity 'Canadian Institutes of Health Research' named entity 'France' named entity 'outpatient clinics' named entity 'H1N1' named entity 'outpatient' named entity 'confounding' named entity 'UK Academy of Medical Sciences' named entity 'metaanalysis' named entity 'ICMJE' named entity 'outpatient' named entity 'PROSPERO' named entity 'seasonal influenza' named entity 'respiratory illness' named entity 'effect size' named entity 'pneumonia' named entity 'pregnant women' named entity 'chronic illness' named entity 'British Columbia' named entity 'symptom'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software